Latest from Telomir
Thu Feb 5, 2026 08:00 am
Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging
Mon Jan 5, 2026 08:00 am
Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models
Thu Dec 18, 2025 07:30 am
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development
Tue Nov 25, 2025 08:00 am
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells
Fri Nov 21, 2025 07:30 am
Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells
Wed Nov 12, 2025 08:00 am
Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line
Thu Oct 23, 2025 07:30 am
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's "Kill-and-Clean" Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo
Tue Oct 21, 2025 07:30 am
Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth
Tue Oct 14, 2025 08:00 am